Related Experiment Video
Updated: Jun 13, 2025
06:18
Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1
Published on: March 13, 2018
14.2K
Trimodal Multiplexed Lateral Flow Test Strips Assisted with a Portable Microfluidic Centrifugation Device
Man-Wen Wang1, Zong-Min Chen1, Yung-Chun Hsieh2
1Department of Applied Chemistry, National Yang Ming Chiao Tung University, Hsinchu 30010, Taiwan.
Analytical Chemistry
|September 14, 2024
Summary
This study introduces a novel trimodal lateral flow assay (LFA) that enhances sensitivity and allows multiplexed detection. The innovative probe design improves diagnostic accuracy for biomarkers like CYFRA 21-1 and CA15-3.
Area of Science:
- Biotechnology
- Nanotechnology
- Medical Diagnostics
Background:
- Lateral flow assays (LFAs) saw increased use during COVID-19 but often lack sensitivity and specificity compared to ELISA and PCR.
- Previous attempts to improve LFAs have increased complexity, hindering large-scale point-of-care applications.
- There is a need for more sensitive, specific, and multiplexed LFAs for diverse diagnostic applications.
Purpose of the Study:
- To develop a novel trimodal probe for enhancing LFA sensitivity and selectivity.
- To enable multiplexed detection of multiple analytes using a single LFA platform.
- To demonstrate the feasibility of this platform for cancer biomarker detection.
Main Methods:
- Developed a trimodal nanohybrid probe integrating fluorescence, color, and magnetic signals.
- Utilized gold nanoparticles and polymer dots for enhanced optical detection.
- Incorporated magnetic properties for accurate quantitative measurements.
- Tested the platform using CYFRA 21-1 (lung cancer) and CA15-3 (breast cancer) biomarkers.
Main Results:
- Achieved a remarkable detection limit of 0.26 ng/mL for CYFRA 21-1 and 2.8 U/mL for CA15-3.
- Demonstrated the first trimodal LFA with multiplexing capability.
- Validated the platform's accuracy and reliability using clinical serum samples, showing high consistency with electrochemiluminescence immunoassay.
Conclusions:
- The developed trimodal LFA platform significantly enhances sensitivity and selectivity.
- This universal platform enables multiplexed detection and has broad applicability for next-generation LFAs.
- The approach offers a promising solution for advanced point-of-care diagnostics.
